An exploratory DEXA analysis of the STEP 1 trial found that semaglutide produced a 9.7% reduction in total lean body mass over 68 weeks alongside a 19.3% reduction in total fat mass, meaning fat was lost at roughly twice the rate of lean tissue
Although current human data remain inconclusive regarding GLP-1 receptor expression in thyroid cells, the FAERS findings reinforce the necessity of continued research and post-market surveillance
Thus, the FDA recommends a patient never take a compounded medication if an FDA-approved version of the medicine is available
For example, with NAD+, despite little evidence of benefit in humans, there are laboratory research findings that it has a role in cancer
Early observational studies suggested lower colorectal cancer incidence among patients treated with GLP-1 agents compared with those receiving other glucose-lowering therapies
However, we do accept HSA and FSA cards for treatment and services